Navigation Links
NW Bio To Review Its Leadership Position In Immune Therapy At The 25th Annual Roth Conference
Date:3/19/2013

ffectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe.  The Company has a broad platform technology for DCVax® dendritic cell-based vaccines.  The Company's lead program is a 312-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal brain cancer.  The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I/II trials in multiple other cancers.  The Company has also conducted a Phase I/II trial with DCVax® for metastatic ovarian cancer together with the University of Pennsylvania. 

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax® and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy.  Additional information on these and other factors, including Ri
'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. At RSNA, DR Systems Will Exhibit RIS, Reporting, Peer Review Systems
2. Nucleic Acids Research Journal Publishes Sapphire Energy Peer-Reviewed Research Paper on a Chloroplast Genome From Green Algae
3. Unigenes 2011 Year in Review - Key Elements in Place to Address Debt in 2012
4. FDAs Oncologic Drugs Advisory Committee to Review Resubmitted Pixantrone New Drug Application on February 9, 2012
5. Nonprofit Consortium Publishes Review of Skullcap Adulteration
6. Peer-reviewed Article Reports ProImmune's Immune Formulation 200® Activates the Immune-Support Gene Nrf2.
7. Vitamin D Deficiency Disorders Global Clinical Trials Review, H2, 2012
8. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its Second Quarter 2012 Financials
9. Inflammatory Bowel Disease Global Clinical Trials Review, H2, 2012
10. Alzheimers Therapeutics Reviewed by NeuroPerspective
11. Peer Reviewed Clinical Study Shows New Blood Test More Accurately Predicts Risk Of A Heart Attack
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Terascala, the industry leader in ... a former vice president of product management for Flexera ... of marketing. Terascala’s software when combined with leading compute ... highest performance and most reliable solutions for processing big ... channel expansion and broaden its product portfolio. His leadership ...
(Date:7/10/2014)... 2014 Robert Harman, DVM, Founder and CEO ... proud to announce the relaunch of his highly informative blog, ... series called “ What are Stem Cells ?” Dr. ... straightforward foundation in the basics of stem cell therapy so ... right type of treatment when considering regenerative medicine. , A ...
(Date:7/10/2014)... EvoDerma ’s NOOME Anti-Aging Motion has been upgraded ... with a second treatment cup to help prevent and smooth ... is thinner on the edges for a softer contact with ... uneven surfaces on the face, neck and décolleté. Choose to ... areas such as the cheeks and neck, or opt for ...
(Date:7/10/2014)... POINT, Ind. , July 10, 2014 ... expanded its use of capnography for respiratory ... growing group of healthcare leaders in embracing ... measures how effectively patients are breathing and ... depression occurs. By measuring the amount of ...
Breaking Biology Technology:Terascala Expands Executive Team 2Terascala Expands Executive Team 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2
... Leader in, Animal Health and Strengthens Product Pipeline, Adding ... ... Projects, KENILWORTH, N.J., Nov. 19 Schering-Plough,Corporation (NYSE: ... BioSciences N.V., creating a stronger combined,company with broader human and animal ...
... discovery of a new way to manipulate light a million ... Science this week. , Using a special hollow-core photonic ... has opened the door to what could prove to be ... and trapping. , The team, led by Dr Fetah Benabid, ...
... The Committee for,Medicinal Products for Human Use ... (EMEA), granted Abbott (NYSE: ABT ) a ... treatment,of moderate to severe plaque psoriasis. Psoriasis will ... is a non-contagious, chronic autoimmune disease that causes,the ...
Cached Biology Technology:Schering-Plough Completes Acquisition of Organon BioSciences 2Schering-Plough Completes Acquisition of Organon BioSciences 3Schering-Plough Completes Acquisition of Organon BioSciences 4Schering-Plough Completes Acquisition of Organon BioSciences 5Discovery of a new way to manipulate light a million times more efficiently 2Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis 2Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis 3Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis 4Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis 5Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis 6Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis 7Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis 8
(Date:7/10/2014)... , July 7, 2014 ... Market Research "Electronic Access Control Systems Market Global Forecast, ... 2019," the global Electronic Access Control systems market was ... expected to grow at a CAGR of 12.6% from ... USD 31,187.8 million in 2019. Browse the ...
(Date:7/10/2014)... The genus Axinaea belongs to the large, mainly ... the ca. 5000 species in the family rely on bees ... pollinated by other insects or vertebrates. The flowers of ... twenty flowers and the petals of the different species are ... stand out based on the contrasting colours of their bulbous ...
(Date:7/10/2014)... or even improve the state of fisheries resources ... the Mediterranean has deteriorated over the past 20 ... species reported in the Cell Press journal ... for stringent monitoring of Mediterranean fishing activities, better ... in Mediterranean waters. , Their data show that ...
Breaking Biology News(10 mins):Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 3Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 4Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 5Novel type of bird pollination mechanism discovered in South America 2Mediterranean fish stocks show steady decline 2
... be enough to cool a hot temper, at least for a ... people who drank a glass of lemonade sweetened with sugar acted ... people who consumed lemonade with a sugar substitute. Researchers believe ... found in the bloodstream that provides energy for the brain. ...
... shows that anti-microbial medications are a common cause of ... (ALF), with women and minorities disproportionately affected. While ALF ... is unlikely; however liver transplantation offers an excellent survival ... published in the December issue of Hepatology , ...
... Washington, D.C. - U.S Energy Secretary Steven Chu today ... time to 57 innovative research projects - using computer ... would be impossible or impractical in the natural world. ... equal to 135,000 quad-core laptops, the research could, for ...
Cached Biology News:Researchers find link between sugar, diabetes and aggression 2Researchers find link between sugar, diabetes and aggression 3Researchers find link between sugar, diabetes and aggression 4Study finds anti-microbials a common cause of drug-induced liver injury and failure 2Could 135,000 laptops help solve the energy challenge? 2Could 135,000 laptops help solve the energy challenge? 3Could 135,000 laptops help solve the energy challenge? 4
... Edited by John M. Walker (1996) ... successful analytical techniques for studying proteins ... protocol contains detailed, step-by-step instruction, timesaving ... and comprehensive lists of reagents and ...
RAT ANTI MOUSE TCR V BETA 7:RPE Immunogen: T-cell lymphoma TK1...
Human/Mouse/Rat Keap1 MAb (Clone 333116) Protein Family: Transcription Factor Regulators...
... 4503277 Accession Number: NP_001912.1 ... the nucleotide substrate for thymidylate synthetase. ... O = dUMP + NH 3 ... the Diseases: Benign Tumor; Leukemia; Escherichia ...
Biology Products: